[8-K] SELLAS Life Sciences Group, Inc. Reports Material Event

Rhea-AI Filing Summary

SELLAS Life Sciences Group disclosed that it has issued a press release announcing its financial results for the quarter ended June 30, 2025 and providing a corporate update. The press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated by reference, but the company states the press release is furnished and not deemed "filed" for purposes of certain securities laws.

The Form identifies the registrant and trading symbol SLS on Nasdaq, provides principal office contact details, and is signed by John T. Burns, Senior Vice President and Chief Financial Officer. The 8-K itself does not present the underlying financial figures; readers must consult Exhibit 99.1 for complete results and the corporate update.

Positive

• Press release furnished as Exhibit 99.1 provides investors with the announced quarterly results and a corporate update
• Disclosure identifies the company and trading symbol (SLS), maintaining regulatory transparency

Negative

• The Form 8-K does not include the actual financial figures or detailed metrics; readers must consult Exhibit 99.1
• Information is explicitly "furnished" and not "filed", which limits certain statutory liabilities and may affect legal recourse based on the filing alone

Insights

Financial Analyst

TL;DR: Routine disclosure; press release furnished but no financials in the 8-K reduces immediate market impact.

The filing notifies investors that quarterly results and a corporate update were released via a press release attached as Exhibit 99.1. Because the Form merely furnishes the press release and explicitly states the content is "not filed," there is limited incremental legal exposure and no additional financial detail included in the 8-K itself. Investors and analysts must review Exhibit 99.1 to assess revenue, earnings, cash position, or any operational changes before drawing conclusions.

Corporate Governance Expert

TL;DR: Disclosure process follows standard practice; "furnished" designation limits Section 18 liabilities.

The company followed a common compliance route by furnishing a press release as an exhibit rather than filing it, which satisfies public disclosure while limiting certain statutory liabilities. The Form includes the required exhibit list and an authorized officer signature. From a governance standpoint, the filing is procedural and does not, by itself, change board composition, executive roles, or corporate governance policies.

0001390478FALSE00013904782025-08-122025-08-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): August 12, 2025

 SELLAS Life Sciences Group, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-33958

20-8099512

(State or other jurisdiction of incorporation or organization)

(Commission File Number)

(I.R.S. Employer Identification No.)

7 Times Square, Suite 2503 New York, NY 10036

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (646) 200-5278

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading symbol(s)			Name of each exchange on which registered
Common Stock, $0.0001 par value per share			SLS			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 12, 2025, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2025 and providing a corporate update.

A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the SEC made by SELLAS whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01.    Financial Statements and Exhibits.

(d)    Exhibits

Exhibit Number						Description
99.1						Press Release dated August 12, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SELLAS Life Sciences Group, Inc.

Date:

August 12, 2025

By:

/s/ John T. Burns

Name:

John T. Burns

Title:

Senior Vice President, Chief Financial Officer

FAQ

What did SELLAS (SLS) disclose in this 8-K?

The company furnished a press release announcing its financial results for the quarter ended June 30, 2025 and provided a corporate update; the press release is attached as Exhibit 99.1.

Are the financial results included directly in the Form 8-K?

No. The Form 8-K states the press release is furnished but does not embed the underlying financial figures; review Exhibit 99.1 for the full results.

Is the press release in Exhibit 99.1 considered "filed" with the SEC?

No. The 8-K explicitly states the information furnished as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and certain sections of the Securities Act.

Who signed the Form 8-K for SELLAS?

The Form is signed by John T. Burns, Senior Vice President and Chief Financial Officer.

Where is the company listed and what is the ticker?

SELLAS Life Sciences Group is listed on The Nasdaq Stock Market under the ticker SLS.